Michele P. Calos
  • Department of Genetics, Stanford University, USA
Research fields
  • Plant science
Personal information


Ph.D of Biochemistry and Molecular Biology, Harvard University, USA

Current position

Professor, Department of Genetics, Stanford University School of Medicine, Stanford, California, USA

Publications (since 2011)

  1. Farruggio, A. P., Bhakta, M. S., du Bois, H., Ma, J. and M, P. C. (2017). Genomic integration of the full-length dystrophin coding sequence in Duchenne muscular dystrophy induced pluripotent stem cells. Biotechnol J.
  2. Calos, M. P. (2017). Genome Editing Techniques and Their Therapeutic Applications. Clin Pharmacol Ther 101(1): 42-51.
  3. Calos, M. P. (2016). The CRISPR Way to Think about Duchenne's. N Engl J Med 374(17): 1684-1686.
  4. Turan, S., Farruggio, A. P., Srifa, W., Day, J. W. and Calos, M. P. (2016). Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy. Mol Ther 24(4): 685-696.
  5. Calos, M. P. (2016). Phage integrases for genome editing. In Cathomen, T., Hirsch, M. and Porteus, M. (Eds). Genome Editing:  The Next Step in Gene Therapy. Springer, 895: 81-91.
  6. Geisinger, J. M., Turan, S., Hernandez, S., Spector, L. P. and Calos, M. P. (2016). In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining. Nucleic Acids Res 44(8): e76.
  7. Woodard, L. E. and Calos, M. P. (2015). Nonviral genome modification strategies for gene therapy: Transposon, integrase, and nuclease systems. In: Templeton, N. S. (Ed). Gene and Cell Therapy Therapeutic Mechanisms and Strategies, Fourth Edition. CRC Press, 675-700.
  8. Geisinger, J. M. and Calos, M. P. (2015). Using phage integrases in a site-specific dual integrase cassette exchange strategy. Methods Mol Biol 1239: 29-38.
  9. Farruggio, A. P. and Calos, M. P. (2014). Serine integrase chimeras with activity in E. coli and HeLa cells. Biol Open 3(10): 895-903.
  10. Zhao, C., Farruggio, A. P., Bjornson, C. R., Chavez, C. L., Geisinger, J. M., Neal, T. L., Karow, M. and Calos, M. P. (2014). Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS One 9(4): e96279.
  11. Zhu, F., Gamboa, M., Farruggio, A. P., Hippenmeyer, S., Tasic, B., Schule, B., Chen-Tsai, Y. and Calos, M. P. (2014). DICE, an efficient system for iterative genomic editing in human pluripotent stem cells. Nucleic Acids Res 42(5): e34.
  12. Tremblay, J. P., Xiao, X., Aartsma-Rus, A., Barbas, C., Blau, H. M., Bogdanove, A. J., Boycott, K., Braun, S., Breakefield, X. O., Bueren, J. A., Buschmann, M., Byrne, B. J., Calos, M., Cathomen, T., Chamberlain, J., Chuah, M., Cornetta, K., Davies, K. E., Dickson, J. G., Duchateau, P., Flotte, T. R., Gaudet, D., Gersbach, C. A., Gilbert, R., Glorioso, J., Herzog, R. W., High, K. A., Huang, W., Huard, J., Joung, J. K., Liu, D., Liu, D., Lochmuller, H., Lustig, L., Martens, J., Massie, B., Mavilio, F., Mendell, J. R., Nathwani, A., Ponder, K., Porteus, M., Puymirat, J., Samulski, J., Takeda, S., Thrasher, A., VandenDriessche, T., Wei, Y., Wilson, J. M., Wilton, S. D., Wolfe, J. H. and Gao, G. (2013). Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther 21(2): 266-268.
  13. Geisinger, J. M. and Calos, M. P. (2013). Site-specific recombination using phiC31 integrase. In: Renault, S. and Duchateau, P. (Eds). Site-directed insertion of transgenes. Springer, 211 - 239.
  14. Farruggio, A. P., Chavez, C. L., Mikell, C. L. and Calos, M. P. (2012). Efficient reversal of phiC31 integrase recombination in mammalian cells. Biotechnol J 7(11): 1332-1336.
  15. Lan, F., Liu, J., Narsinh, K. H., Hu, S., Han, L., Lee, A. S., Karow, M., Nguyen, P. K., Nag, D., Calos, M. P., Robbins, R. C. and Wu, J. C. (2012). Safe genetic modification of cardiac stem cells using a site-specific integration technique. Circulation 126(11 Suppl 1): S20-28.
  16. Hillman, R. T. and Calos, M. P. (2012). Site-specific integration with bacteriophage PhiC31 integrase. Cold Spring Harb Protoc 2012(5).
  17. Chavez, C. L., Keravala, A., Chu, J. N., Farruggio, A. P., Cuellar, V. E., Voorberg, J. and Calos, M. P. (2012). Long-term expression of human coagulation factor VIII in a tolerant mouse model using the phiC31 integrase system. Hum Gene Ther 23(4): 390-398.
  18. Karow, M., Chavez, C. L., Farruggio, A. P., Geisinger, J. M., Keravala, A., Jung, W. E., Lan, F., Wu, J. C., Chen-Tsai, Y. and Calos, M. P. (2011). Site-specific recombinase strategy to create induced pluripotent stem cells efficiently with plasmid DNA. Stem Cells 29(11): 1696-1704.
  19. Chavez, C. L. and Calos, M. P. (2011). Therapeutic applications of the PhiC31 integrase system. Curr Gene Ther 11(5): 375-381.
  20. Karow, M. and Calos, M. P. (2011). The therapeutic potential of PhiC31 integrase as a gene therapy system. Expert Opin Biol Ther 11(10): 1287-1296.
  21. Keravala, A., Chavez, C. L., Hu, G., Woodard, L. E., Monahan, P. E. and Calos, M. P. (2011). Long-term phenotypic correction in factor IX knockout mice by using PhiC31 integrase-mediated gene therapy. Gene Ther 18(8): 842-848.
  22. Ito, M., Yamanouchi, K., Naito, K., Calos, M. P. and Tojo, H. (2011). Site-specific integration of transgene targeting an endogenous lox-like site in early mouse embryos. J Appl Genet 52(1): 89-94.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.